Bankruptcy Personal Injury Accidents Automobile Accidents and Injuries Animal Attacks Automobile Negligence Bodily Injury Catastrophic Injury Dog Bites Head Injury Pedestrian Injuries Plaintiffs Personal Injury Wrongful Death Whiplash Unintended Acceleration Traumatic Brain Injury Tourist Injuries TMJ Dysfunction Third Party Wrongful Death Transfusion Associated AIDS Spinal Injury Slip and Fall Sexual Abuse Severe Burns School Bus Accidents Repetitive Stress Injury Rental Vehicle Litigation Psychological Injury Power Line Contact Injury Personal Injury Mediation Neurolaw Motorcycle Accidents Motor Vehicle Accidents and Injuries Electromagnetic Field Litigation Electrical Injury Cumulative Trauma Commercial Vehicle Liability Bus Accidents Carpal Tunnel Syndrome Brain Injury Boating Accidents Bicycle Accidents Aquatic Injuries AIDS Litigation
ISLN:
917326798
Admitted:
2002
University:
Nova Southeastern University, M.S.
Law School:
Barry University Dwayne O. Andreas School of Law, 2002; Barry University School of Law, J.D.
Name / Title
Company / Classification
Phones & Addresses
Deborah Higgins Vice President
Theravance, Inc. Pharmaceutical Preparations
901 Gateway Blvd, South San Francisco, CA 94080
Deborah E Higgins
HIGGINS CONSTRUCTION, INC
Us Patents
Composition And Methods Of Making And Using Influenza Proteins
Gary VAN NEST - Martinez CA, US Brian D. LIVINGSTON - Martinez CA, US Georg ROTH - San Anselmo CA, US Deborah A. HIGGINS - Danville CA, US
International Classification:
A61K 9/127 A61K 9/14 A61K 39/145
US Classification:
424450, 424489, 4242091
Abstract:
The invention provides compositions of influenza proteins, such as matrix and nucleoprotein, that are presented to an individual's immune system as multimeric displays to induce an immune response. The compositions are optionally associated with any type of immunomodulatory compound (IMC) comprising an immunostimulatory sequences (ISS). The invention further provides compositions of influenza matrix and nucleoproteins that can induce cellular and/or humoral immune response. The invention also provides methods of making and using these compositions, e.g., as a vaccine, for ameliorating symptoms associated with infection with influenza virus or for reducing the risk of infection with influenza virus.
Compositions And Methods Of Making And Using Influenza Proteins
Gary Van Nest - Martinez CA, US Brian D. Livingston - Martinez CA, US Georg Roth - San Anselmo CA, US Deborah A. Higgins - Danville CA, US
International Classification:
A61K 39/145
US Classification:
424450, 4241861, 530358
Abstract:
The invention provides compositions of influenza proteins, such as matrix and nucleoprotein, that are presented to an individual's immune system as multimeric displays to induce an immune response. The compositions are optionally associated with any type of immunomodulatory compound (IMC) comprising an immunostimulatory sequences (ISS). The invention further provides compositions of influenza matrix and nucleoproteins that can induce cellular and/or humoral immune response. The invention also provides methods of making and using these compositions, e.g., as a vaccine, for ameliorating symptoms associated with infection with influenza virus or for reducing the risk of infection with influenza virus.
Stephen P. Anderson - San Mateo CA Deborah L. Higgins - San Mateo CA Adair J. Hotchkiss - Half Moon Bay CA Cara B. Marks - San Francisco CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
C12N 1558 C12N 1500
US Classification:
435226
Abstract:
Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof demonstrate increased half-life profiles, and show good fibrin binding activity even though fibrin binding regions of the molecule are deleted. All associated means and methods for preparing such variants recombinantly and for using such variants are also disclosed.
Deborah L. Higgins - San Mateo CA William E. Holmes - Pacifica CA Adair J. Hotchkiss - Half Moon Bay CA
Assignee:
Genentech, Inc. - S. San Francisco CA
International Classification:
A61K 37547 C12N 950 C12N 964
US Classification:
424 9464
Abstract:
Disclosed herein are improved processes for preparing variant human t-PA proteins exhibiting improved pharmacokinetic properties relative to natural t-PA. One such illustrated variant, devoid of amino acids corresponding to amino acids 1 through 44 of natural t-PA, is shown to exhibit a plasma half-life of greater than about 15 times the plasma half-file of natural t-PA, as well as a clearance rate of less than about 1/10 the clearance rate of natural t-PA. Also disclosed are improved processes for treating vascular disease employing pharmaceutical compositions which incorporate therapeutically effective amounts of such t-PA variants with pharmaceutically acceptable diluents or excipients.
Stephen P. Anderson - San Mateo CA Deborah L. Higgins - San Mateo CA Adair J. Hotchkiss - Half Moon Bay CA Cara B. Marks - San Francisco CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
C12N 964 C12N 1500 C12N 948 C12N 972
US Classification:
435226
Abstract:
Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof demonstrate increased half-life profiles, and show good fibrin binding activity even though fibrin binding regions of the molecule are deleted. All associated means and methods for preparing such variants recombinantly and for using such variants are also disclosed.
Deborah L. Higgins - San Mateo CA William E. Holmes - Pacifica CA Adair J. Hotchkiss - Half Moon Bay CA
Assignee:
Genentech, Inc. - San Francisco CA
International Classification:
A61K 37547 C12N 1558 C12N 964
US Classification:
424 9464
Abstract:
Disclosed herein are improved processes for preparing variant human t-PA proteins exhibiting improved pharmacokinetic properties relative to natural t-PA. One such illustrated variant, devoid of amino acids corresponding to amino acids 1 through 44 of natural t-PA, is shown to exhibit a plasma half-life of greater than about 15 times the plasma half-life to natural t-PA, as well as a clearance rate of less than about 1/10 the clearance rate of natural t-PA. Also disclosed are improved processes for treating vascular disease employing pharmaceutical compositions which incorporate therapeutically effective amounts of such t-PA variants with pharmaceutically acceptable diluents or excipients.
Stephen P. Anderson - San Mateo CA Deborah L. Higgins - San Mateo CA Adair J. Hotchkiss - Half Moon Bay CA Cara B. Marks - San Francisco CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
C12N 964 C12N 1500 C12N 1558
US Classification:
435226
Abstract:
Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof demonstrate increased half-life profiles, and show good fibrin binding activity even though fibrin binding regions of the molecule are deleted. All associated means and methods for preparing such variants recombinantly and for using such variants are also disclosed.
Stephen P. Anderson - San Mateo CA Deborah L. Higgins - San Mateo CA Adair J. Hotchkiss - Half Moon Bay CA Cara B. Marks - San Francisco CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
C12N 964 C12N 948 C12N 972
US Classification:
435226
Abstract:
Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof demonstrate increased half-life profiles, and show good fibrin binding activity even though fibrin binding regions of the molecule are deleted. All associated means and methods for preparing such variants recombinantly and for using such variants are also disclosed.
My wife Deborah adores this band, says ATP founder Barry Hogan, who has been organizing ATP events with his wife Deborah Higgins since 2004. When we first started dating she would always say we had to get the Afghan Whigs to play for us. I used to love going to see them. They always sounded great